We work hard to bring you the stories about the life science community in North Carolina. Every once in a while, we add a little news of our own. Read some of those stories below, or check out some of our perspectives on our staff blog.
The U.S. Food and Drug Administration has approved ViiV Healthcare’s two-drug, once-a-day tablet combination to treat infection by a certain type of the human immunodeficiency virus (HIV).
The therapy, Juluca, consists of two previously approved drugs, dolutegravir and rilpivirine. It is the first approved HIV treatment that combines two drugs instead of three or more used in standard HIV treatment. And it's significant that it's a once-daily tablet.
Ken Tindall, Ph.D., senior vice president of science and business development at the North Carolina Biotechnology Center, has won Southeast BIO’s Leadership Award, one of several honors announced at SEBIO’s 19th Annual Investor and Partnering Forum in Pinehurst.
Thirty-five years after its founding in 1982, Durham-based QuintilesIMS has retired its name for a new one, IQVIA (pronounced as “I-Q-via”).
Shares of IQVIA will trade on the New York Stock Exchange under the new ticker symbol IQV, effective Nov. 15.